Addis Pharmaceutical Factory
Addis Pharmaceutical Factory manufactures high-quality pharmaceutical products such as antibiotics, cardiovascular drugs and much more
About Addis Pharmaceutical Factory
Addis Pharmaceutical Factory PLC (APF) is a significant player in the Ethiopian pharmaceutical manufacturing sector, established in 1992 with operations commencing in 1997. The company's main high-tech production facility and headquarters are located in Adigrat, Tigray, with a second plant dedicated to large volume intravenous infusions in Addis Ababa. The initial establishment was supported by the Endowment Fund for the Rehabilitation of Tigray (EFFORT).
APF's business revolves around the manufacturing and distribution of a wide array of generic pharmaceutical products. The company serves various clients within Ethiopia, including wholesalers, pharmacies, and health centers, aiming to satisfy the country's demand for essential drugs at accessible prices. Its business model is centered on large-scale production and local market penetration. In 2016, 54 Capital, an Africa-focused private equity firm, made a substantial investment of $42 million to enhance production capacity, expand the product portfolio, and pursue World Health Organization (WHO) certification, signaling a strategy for both national and international growth.
The company boasts a diverse product portfolio of over 91 different drugs across numerous therapeutic categories. These include antibiotics, analgesics, cardiovascular drugs, central nervous system agents, antidiabetics, and vitamins. APF produces a variety of dosage forms through more than nine production lines, such as tablets, capsules, syrups, injections, ointments, and sterile powders. The annual production capacity is substantial, reportedly including 1.2 billion tablets, 19 billion ampoules, and 10 million vials, positioning APF as one of the largest drug manufacturers in Ethiopia. The company has received a Good Manufacturing Practice (GMP) certification from Ethiopian regulatory authorities, underscoring its commitment to quality.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 18.0/100
- Industry
- Health
- Sector
- Testing, Verification, Drug Development, Cardiology and cardiovascular, Pharmaceutical, Hard Tech, medical testing
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2016 | $42M | $168M | 54 Capital | — |
Growth signals
Latest recorded traffic for Addis Pharmaceutical Factory is 180 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Addis Pharmaceutical Factory in the La Tigra ecosystem
The Addis Pharmaceutical Factory office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
54 Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Addis Pharmaceutical Factory on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Addis Pharmaceutical Factory’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









